RPR-109891

• Description :

  RPR-109891 is an orally active glycoprotein IIb/IIIa peptide antagonist. RPR-109891 can decrease platelet count and reduce platelet survival time. RPR-109891 can be used for the research of cardiovascular disease, such as myocardial infarction[1][2].

• UNSPSC :

  12352005

• Target :

  Integrin

• Related Pathways :

  Cytoskeleton

• Field of Research :

  Cardiovascular Disease

• Smiles :

  O=C(CCCC1CCNCC1)N(CC)CC(N[C@@H](CC(O)=O)C(N[C@H](C(N)=O)CC2CCCCC2)=O)=O

• Molecular Formula :

  C26H45N5O6

• Molecular Weight :

  523.67

• References & Citations :

  [1]Weiss DJ, et al. Platelet kinetics in dogs treated with a glycoprotein IIb/IIIa peptide antagonist. Toxicol Pathol. 2000 Mar-Apr;28 (2) :310-6.|[2]Giugliano RP, et al. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J. 2000 Jul;140 (1) :81-93.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [169512-56-5]